

# **Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis**

Audrey D Zhang, Jeremy Puthumana, Nicholas S Downing,  
Nilay D Shah, Harlan M Krumholz, Joseph S Ross

## **SUPPLEMENTARY FILE**

### **SUPPLEMENTARY FILE CONTENTS**

#### **Box S1. Special Regulatory Program Characteristics**

**Table S2. Randomization and Blinding of Pivotal Trials Supporting New Drugs and Biologics Across Three Periods, Considering Trials with Comparator Arms Only**

**Table S3. Drugs Approved Without Pivotal Efficacy Trials**

**Table S4. Completeness of Pivotal Trial Characteristics Reporting Among 1995-1997 Sample**

**Table S5. Completeness of Pivotal Trial Characteristics Reporting Among Indication-Level Approvals**

**Table S6. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Drug Type**

**Table S7. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Drug Type**

**Table S8. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Therapeutic Area**

**Table S9. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Therapeutic Area**

**Table S10. Duration of Pivotal Trials Supporting New Drugs and Biologics Across Three Time Periods, Stratified by Expected Length of Treatment**

**Table S11. Duration of Pivotal Trials Included in Indication-Level Approvals for Novel Therapeutics, Stratified by Expected Length of Treatment**

**Table S12. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Individual Special Regulatory Programs**

**Table S13. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Individual Special Regulatory Programs**

**Table S14. Characteristics of Pivotal Trials Supporting Novel Therapeutics Approved by the FDA Across Three Time Periods, Considering Orphan Designation as a Special Regulatory Program**

**Table S15. Characteristics of Indication-Level Approvals for Novel Therapeutics Approved by the FDA Across Three Time Periods, Considering Orphan Designation as a Special Regulatory Program**

**Box S1. Special Regulatory Program Characteristics**

<b>Program</b>	<b>Year</b>	<b>Eligibility Criteria</b>	<b>Benefits</b>
Fast Track	1988 (Subpart H) 1997 (FDAMA)	<ul style="list-style-type: none"> <li>• Drug treats a serious condition</li> <li>• Data demonstrate the potential to address unmet medical need</li> </ul> <p>OR</p> <ul style="list-style-type: none"> <li>• Drug designated as qualified infectious disease product</li> </ul>	<ul style="list-style-type: none"> <li>• Actions to expedite development and review, including meetings with FDA during development</li> </ul>
Priority Review	1992	<ul style="list-style-type: none"> <li>• Drug treats a serious condition</li> <li>• Would provide a significant improvement in safety or effectiveness</li> </ul> <p>OR</p> <ul style="list-style-type: none"> <li>• Drug designated as a qualified infectious disease product</li> </ul> <p>OR</p> <ul style="list-style-type: none"> <li>• Submitted with a priority review voucher</li> </ul>	<ul style="list-style-type: none"> <li>• Shorter clock for review of marketing application</li> </ul>
Accelerated Approval	1992	<ul style="list-style-type: none"> <li>• Drug treats a serious condition</li> <li>• Provides a meaningful advantage over available therapies</li> </ul>	<ul style="list-style-type: none"> <li>• Approval based on effect on surrogate endpoint or intermediate clinical endpoint reasonably likely to predict a drug's clinical benefit</li> </ul>
Breakthrough Designation	2012	<ul style="list-style-type: none"> <li>• Drug intended to treat a serious condition</li> <li>• Preliminary clinical evidence suggests the drug may demonstrate substantial improvement on a clinically-significant endpoint over available therapies</li> </ul>	<ul style="list-style-type: none"> <li>• Intensive guidance on efficient drug development, including meetings with FDA during development that may allow for alternative clinical trial designs</li> <li>• Other actions to expedite review</li> </ul>

Source: FDA Guidance: Expedited Programs for Serious Conditions—Drugs and Biologics.

FDAMA = Food and Drug Administration Modernization Act

**Table S2. Randomization and Blinding of Pivotal Trials Supporting New Drugs and Biologics Across Three Periods, Considering Trials with Comparator Arms Only**

<b>Characteristic</b>	<b>Randomized</b>	<b>Double-Blinded</b>
<b>All Pivotal Trials</b>		
95-97 (n=401)	93.6 (90.7-95.8)	79.4 (75.0-83.3)
05-07 (n=141)	82.2 (74.9-88.2)	67.4 (59.0-75.0)
15-17 (n=253)	82.2 (76.9-86.7)	67.6 (61.4-73.3)
3-way p	P<0.001	P<0.001
<b>Controlled Trials Only</b>		
95-97 (n=367)	100 (99.0-100)	84.4 (80.2-88.0)
05-07 (n=116)	100 (96.9-100)	81.9 (73.7-88.4)
15-17 (n=208)	100 (98.2-100)	82.2 (76.3-87.2)
3-way p	NA	p=0.471

**Table S3. Drugs Approved Without Pivotal Efficacy Trials**

4 drugs in the sample were approved without pivotal efficacy trials, representing 7 indications.

<b>Drug</b>	<b>Year</b>	<b>Indications Without Pivotal Efficacy Trials</b>
Cerbyx (fosphenytoin sodium)	1996	1 - substituted, as short-term use, for oral phenytoin 2 - generalized tonic-clonic status epilepticus 3 - prevention and treatment of seizures occurring during neurosurgery
Albenza (albendazole)	1996	1 - neurocysticercosis 2 - hydatid disease
Cystadine (betaine hydrochloride)	1996	1 - decrease elevated homocysteine blood levels in patients with cystathionine beta-synthase type of homocystinuria; MTHFR deficiency; cobalamin defect
Sclerosol (talc)	1997	1 - treatment of malignant pleural effusions

### Completeness of Trial Characteristics Reporting

**Table S4. Completeness of Pivotal Trial Characteristics Reporting Among 1995-1997 Sample**

Characteristic	Use of Randomization	Use of Double-Blinding	Choice of Comparator	Choice of Endpoint	Overall Treated Patients	Intervention on Treated Patients	Duration
Overall (n=401)	392 (97.8)	393 (98.0)	401 (100)	400 (99.8)	396 (98.8)	391 (97.5)	330 (82.3)
<b>Regulatory Program</b>							
Any (n=85)	85 (100)	82 (96.5)	85 (100)	85 (100)	85 (100)	85 (100)	68 (80.0)
None (n=316)	307 (97.2)	311 (98.4)	316 (100)	315 (99.7)	311 (98.4)	306 (96.8)	266 (84.2)
<b>Orphan</b>							
Yes (n=31)	31 (100)	31 (100)	31 (100)	31 (100)	31 (100)	31 (100)	18 (58.0)
No (n=370)	361 (97.6)	362 (97.8)	370 (100)	369 (99.7)	365 (98.6)	360 (97.3)	311 (84.1)

**Table S5. Completeness of Pivotal Trial Characteristics Reporting Among Indication-Level Approvals**

Characteristic	Choice of Comparator	Choice of Endpoint	Overall Treated Patients	Intervention on Treated Patients	Duration	All Variables
Overall (n=332)	332 (100)	331 (99.7)	330 (99.4)	327 (98.5)	293 (88.3)	293 (88.3)
1995-1997 (n=150)	150 (100)	149 (99.3)	148 (98.7)	145 (96.7)	124 (82.7)	124 (82.7)
2005-2007 (n=64)	64 (100)	64 (100)	64 (100)	64 (100)	63 (98.4)	63 (98.4)
2015-2017 (n=118)	118 (100)	118 (100)	118 (100)	118 (100)	106 (89.8)	106 (89.8)

**Supplementary Analyses: By Drug Type**

**Table S6. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Drug Type**

	Random-ized	Double-Blinded	Comparator			Endpoint			Patients (Median, IQR)		Duration (Median, IQR)
			Active	Placebo	None	Clinical	Scale	Surrogate	Overall	Intervention	Weeks
<b>Drug Type</b>											
Molecule											
95-97 (n=396)	93.7 (90.9-96.0)	79.3 (75.0-83.3)	44.7 (39.7-49.7)	47.0 (42.0-52.0)	8.3 (5.8-11.5)	43.5 (38.6-48.6)	7.8 (5.4-11.0)	48.6 (43.6-53.7)	278 (150-443)	170 (92-277)	9.5 (4.9-24.0)
05-07 (n=125)	80.8 (72.8-87.3)	69.6 (60.7-77.5)	32.8 (24.7-41.8)	48.0 (39.0-57.1)	19.2 (12.7-27.2)	29.6 (21.8-38.4)	8.8 (4.5-15.2)	61.6 (52.5-70.2)	408 (192-627)	251 (138-385)	12.0 (5.0-24.0)
15-17 (n=185)	81.6 (75.3-86.9)	64.9 (57.5-71.7)	29.7 (23.2-36.9)	51.9 (44.4-59.3)	18.4 (13.1-24.7)	22.2 (16.4-28.8)	14.1 (9.4-19.9)	63.8 (56.4-70.7)	464 (217-705)	279 (153-436)	24.0 (12.0-27.4)
3-way p	P<0.001	P<0.001	P<0.001	P=0.23	P<0.001	P<0.001	P=0.02	P<0.001	P<0.001	P<0.001	P<0.001
2-way p	P<0.001	P<0.001	P<0.001			P<0.001			P<0.001	P<0.001	P<0.001
<b>Biologic</b>											
95-97 (n=5)	80.0 (28.4-99.5)	80.0 (28.4-99.5)	0.0 (0.0-5.2)	80.0 (28.4-99.5)	20.0 (0.5-71.6)	60.0 (14.7-94.7)	20.0 (0.5-71.6)	20.0 (0.5-71.6)	172 (150-328)	158 (52-196)	20.0 (20.0-39.3)
05-07 (n=16)	93.8 (69.8-99.8)	50.0 (24.7-75.3)	43.8 (19.8-70.1)	50.0 (24.7-75.3)	6.3 (0.2-30.2)	18.8 (4.0-45.6)	31.3 (11.0-58.7)	50.0 (24.7-75.3)	338 (131-525)	194 (94-338)	36.0 (24.9-52.0)
15-17 (n=68)	83.8 (72.9-91.6)	75.0 (63.0-84.7)	27.9 (17.7-40.1)	55.9 (43.3-67.9)	16.2 (8.4-27.1)	26.5 (16.5-38.6)	26.5 (16.5-38.6)	47.1 (34.8-60.0)	487 (126-835)	308 (86-488)	24.0 (12.0-46.8)
3-way p	P=0.67	P=0.32	P=0.81	P=0.60	P=0.67	P=0.40	P=1.00	P=0.46	P=0.09	P=0.07	P=0.13
2-way p	P=0.84	P=0.82	P=0.38			P=0.27			P=0.18	P=0.14	P=1.00

**Table S7. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Drug Type**

	≥2 Trials (%, 95% CI)	Comparators (%, 95% CI)		Endpoints (%, 95% CI)		Patients in Aggregated Pivotal Efficacy Trials (Median, IQR)		Duration (%, 95% CI)	
		≥1 Trial Using Any Comparator	Single-Arm Only	≥1 Trial Using Clinical Endpoints or Clinical Scales	Surrogate Endpoints Only	Overall	Intervention	≥1 Trial of ≥6 Months	≥1 Trial of ≥12 Months
<b>Drug Type</b>									
Molecule									
95-97 (n=122)	81.1 (73.1-87.7)	95.9 (90.7-98.7)	4.1 (1.3-9.3)	59.8 (50.6-68.6)	40.2 (31.4-49.4)	786 (472-1355)	493 (237-745)	25.4 (18.0-34.1)	18.0 (11.7-26.0)
05-07 (n=55)	63.6 (49.6-76.2)	87.3 (75.5-94.7)	12.7 (5.3-24.5)	47.3 (33.7-61.2)	52.7 (38.8-66.3)	707 (301-1433)	425 (196-808)	29.1 (17.6-42.9)	14.5 (6.5-26.7)
15-17 (n=79)	48.1 (36.7-59.6)	84.8 (75.0-91.9)	15.2 (8.1-25.0)	51.9 (40.4-63.3)	48.1 (36.7-59.6)	796 (220-1820)	445 (200-1092)	44.3 (33.1-55.9)	35.4 (25.0-47.0)
3-way p	P<0.001	P=0.007		P=0.22		P=0.90	P=0.98	P=0.006	P=0.007
2-way p	P<0.001	P=0.006		P=0.27		P=0.99	P=0.90	P=0.005	P=0.005
<b>Biologic</b>									
95-97 (n=2)	50.0 (1.3-98.7)	100 (15.8-100)	0 (0.0-84.2)	100 (15.8-100)	0 (0.0-84.2)	487 (301-672)	255 (158-351)	50.0 (1.3-98.7)	50.0 (1.3-98.7)
05-07 (n=8)	37.5 (8.5-75.5)	87.5 (47.3-99.7)	12.5 (0.3-52.7)	62.5 (24.5-91.5)	37.5 (8.5-75.5)	279 (59-1281)	147 (29-847)	75.0 (34.9-96.8)	50.0 (15.7-84.3)
15-17 (n=27)	66.7 (46.0-83.5)	77.8 (57.7-91.4)	22.2 (8.6-42.3)	63.0 (42.4-80.6)	37.0 (19.4-57.6)	1327 (94-2448)	825 (85-1343)	51.9 (31.9-71.3)	37.0 (19.4-57.6)
3-way p	P=0.21	P=0.35		P=0.46		P=0.20	P=0.12	P=0.49	P=0.51
2-way p	P=0.68	P=0.50		P=0.32		P=0.70	P=0.60	P=1.00	P=0.76

**Supplementary Analyses: By Therapeutic Area**

**Table S8. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Therapeutic Area**

Area	Randomized	Double-Blinded	Comparator			Endpoint			Patients (Median, IQR)		Duration (Median, IQR)
			Active	Placebo	None	Clinical	Scale	Surrogate	Overall	Intervention	Weeks
<b>ID</b>											
95-97 (n=104)	96.0 (90.2-98.9)	72.0 (62.1-80.5)	81.4 (72.4-88.4)	14.7 (8.5-23.1)	3.9 (1.1-9.7)	67.3 (57.3-76.3)	0	32.7 (23.7-42.7)	362 (254-553)	200 (144-294)	5.0 (3.4-7.6)
05-07 (n=29)	96.6 (82.2-99.9)	75.9 (56.5-89.7)	82.8 (64.2-94.2)	13.8 (3.9-31.7)	3.4 (0.1-17.8)	51.7 (32.5-70.6)	0	48.3 (29.4-67.5)	543 (339-662)	292 (234-385)	16.0 (2.3-24.0)
15-17 (n=40)	65.0 (48.3-79.4)	52.5 (36.1-68.5)	32.5 (18.6-49.1)	32.5 (18.6-49.1)	35.0 (20.6-51.7)	27.5 (14.6-43.9)	0	72.5 (56.1-85.4)	405 (167-549)	240 (129-409)	12.0 (11.5-12.0)
3-way p	P<0.001	P=0.05	P<0.001	P=0.02	P<0.001	P<0.001	NA	P<0.001	P=0.56	P=0.07	P=0.001
2-way p	P<0.001	P=0.03	P<0.001			P<0.001			P=0.72	P=0.36	P<0.001
<b>Cancer</b>											
95-97 (n=32)	67.7 (48.6-83.3)	39.3 (21.5-59.4)	38.7 (21.8-57.8)	16.1 (5.5-33.7)	45.2 (27.3-64.0)	22.6 (9.6-41.1)	0	77.4 (58.9-90.4)	235 (112-410)	122 (71-260)	26.0 (9.2-56.4)
05-07 (n=18)	38.9 (17.3-64.3)	11.1 (1.4-34.7)	11.1 (1.4-34.7)	27.8 (9.7-53.5)	5.6 (0.1-27.3)	5.6 (0.1-27.3)	0	94.4 (72.7-99.9)	139 (74-395)	139 (74-209)	17.0 (5.0-24.5)
15-17 (n=40)	52.5 (36.1-68.5)	35.0 (20.6-51.7)	5.0 (0.6-16.9)	47.5 (31.5-63.9)	47.5 (31.5-63.9)	20.0 (9.1-35.6)	0	80.0 (64.4-90.9)	228 (135-598)	215 (124-349)	56.8 (31.5-87.0)
3-way p	P=0.23	P=0.84	P<0.001	P=0.005	P=0.90	P=0.85	NA	P=0.85	P=0.10	P=0.04	P=0.003
2-way p	P=0.20	P=0.73	P<0.001			P=1.00			P=0.14	P=0.05	P=0.06
<b>Cardiovascular</b>											
95-97 (n=113)	99.1 (95.1-100)	87.5 (79.9-93.0)	30.1 (21.8-39.4)	69.0 (59.6-77.4)	0.9 (0.0-4.8)	8.8 (4.3-15.7)	0	91.2 (84.3-95.7)	252 (152-442)	155 (86-327)	12.0 (8.0-25.7)
05-07 (n=33)	90.9 (75.7-98.1)	84.8 (68.1-94.9)	18.2 (7.0-35.5)	72.7 (54.5-87.6)	9.1 (1.9-24.3)	9.1 (1.9-24.3)	0	90.9 (75.7-98.1)	538 (337-688)	387 (241-499)	12.0 (10.7-26.0)
15-17 (n=67)	97.0 (89.6-99.6)	68.7 (56.1-79.4)	53.7 (41.1-66.0)	43.3 (31.2-56.0)	3.0 (0.4-10.4)	14.9 (7.4-25.7)	0	85.1 (74.3-92.6)	484 (365-1020)	313 (221-697)	26.0 (24.0-26.3)
3-way p	P=0.29	P=0.002	P=0.003	P=0.001	P=0.29	P=0.22	NA	P=0.22	P<0.001	P<0.001	P<0.001
2-way p	P=0.30	P=0.002	P=0.003			P=0.31			P<0.001	P<0.001	P<0.001
<b>Other</b>											
95-97 (n=159)	93.2 (87.9-96.7)	85.6 (79.0-90.8)	31.0 (23.8-38.9)	59.4 (51.2-67.2)	9.7 (5.5-15.5)	58.1 (49.9-65.9)	20.6 (14.6-27.9)	21.3 (15.1-28.6)	247 (127-375)	155 (77-250)	12.0 (6.0-24.0)
05-07 (n=61)	83.6 (71.9-91.8)	70.5 (57.4-81.5)	26.2 (15.8-39.1)	57.4 (44.1-70.0)	16.4 (8.2-28.1)	34.4 (22.7-47.7)	26.2 (15.8-39.1)	39.3 (27.0-52.7)	324 (99-522)	181 (83-302)	16.0 (6.0-36.0)
15-17 (n=106)	89.6 (82.2-94.7)	84.9 (76.6-91.1)	21.7 (14.3-30.8)	68.9 (59.1-77.5)	9.4 (4.6-16.7)	28.3 (20.0-37.9)	41.5 (32.0-51.5)	30.2 (21.7-39.9)	544 (195-741)	299 (100-473)	13.4 (12.0-25.2)
3-way p	P=0.39	P=0.71	P=0.10	P=0.14	P=0.95	P<0.001	P<0.001	P=0.08	P<0.001	P<0.001	P=0.06



2-way p	P=0.44	P=0.87	P=0.24	P<0.001	P<0.001	P<0.001	P=0.05
---------	--------	--------	--------	---------	---------	---------	--------

**Table S9. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Therapeutic Area**

	≥2 Trials (%, 95% CI)	Comparators (%, 95% CI)		Endpoints (%, 95% CI)		Patients in Aggregated Pivotal Efficacy Trials (Median, IQR)		Duration (%, 95% CI)	
		≥1 Trial Using Any Comparator	Single-Arm Only	≥1 Trial Using Clinical-Type Endpoints	Surrogate Endpoints Only	Overall	Intervention	≥1 Trial of ≥6 Months	≥1 Trial of ≥12 Months
<b>Area</b>									
<b>ID</b>									
95-97 (n=48)	68.8 (53.7-81.3)	100 (92.6-100)	0 (0.0-7.4)	72.9 (58.2-84.7)	27.1 (15.3-41.8)	761 (464-1106)	436 (236-659)	4.2 (0.5-14.3)	2.1 (0.0-11.1)
05-07 (n=16)	68.8 (41.3-89.0)	100 (79.4-100)	0 (0.0-20.6)	56.3 (29.9-80.2)	43.8 (19.8-70.1)	998 (663-1285)	540 (433-777)	12.5 (1.6-38.3)	6.3 (0.2-30.2)
15-17 (n=16)	62.5 (35.4-84.8)	93.8 (69.8-99.8)	6.3 (0.2-30.2)	50.0 (24.7-75.3)	50.0 (24.7-75.3)	647 (305-1644)	344 (177-1157)	12.5 (1.6-38.3)	6.3 (0.2-30.2)
3-way p	P=0.68	P=0.08		P=0.07		P=0.72	P=0.59	P=0.20	P=0.37
2-way p	P=0.65	P=0.09		P=0.10		P=0.84	P=1.00	P=0.24	P=0.43
<b>Cancer</b>									
95-97 (n=7)	57.1 (18.4-90.1)	71.4 (29.0-96.3)	28.6 (3.7-71.0)	14.3 (0.4-57.9)	85.7 (42.1-99.6)	373 (244-713)	225 (125-389)	71.4 (29.0-96.3)	57.1 (18.4-90.1)
05-07 (n=11)	36.4 (10.9-69.2)	63.4 (30.8-89.1)	36.4 (10.9-69.2)	9.1 (0.2-41.3)	90.9 (58.7-99.8)	389 (191-594)	207 (191-411)	27.3 (6.0-61.0)	9.1 (0.2-41.3)
15-17 (n=26)	19.2 (6.6-39.4)	53.8 (33.4-73.4)	46.2 (26.6-66.6)	19.2 (6.6-39.4)	80.8 (60.6-93.4)	402 (195-710)	286 (195-371)	84.6 (65.1-95.6)	61.5 (40.6-79.8)
3-way p	P=0.04	P=0.36		P=0.59		P=0.88	P=0.39	P=0.08	P=0.24
2-way p	P=0.05	P=0.43		P=0.79		P=0.91	P=0.45	P=0.45	P=0.85
<b>Cardiovascular</b>									
95-97 (n=25)	88.0 (68.8-97.5)	100 (86.3-100)	0 (0.0-13.7)	16.0 (4.5-36.1)	84.0 (63.9-95.5)	1370 (652-2322)	985 (367-1555)	44.0 (24.4-65.1)	28.0 (12.1-49.4)
05-07 (n=10)	80.0 (44.4-97.5)	100 (69.2-100)	0 (0.0-30.8)	20.0 (2.5-55.6)	80.0 (44.4-97.5)	1724 (469-2339)	1235 (275-1621)	40.0 (12.2-73.8)	10.0 (0.3-44.5)
15-17 (n=15)	46.7 (21.3-73.4)	93.3 (68.1-99.8)	6.7 (0.2-31.9)	46.7 (21.3-73.4)	53.3 (26.6-78.7)	5288 (2284-8107)	3232 (1528-4052)	66.7 (38.4-88.2)	66.7 (38.4-88.2)
3-way p	P=0.005	P=0.16		P=0.04		P=0.002	P=0.003	P=0.19	P=0.03
2-way p	P=0.005	P=0.22		P=0.04		P=0.002	P=0.002	P=0.18	P=0.02
<b>Other</b>									
95-97 (n=44)	93.2 (81.3-98.6)	93.2 (81.3-98.6)	6.8 (1.4-18.7)	79.5 (64.7-90.2)	20.5 (9.8-35.3)	766 (526-950)	479 (311-617)	31.8 (18.6-47.6)	25.0 (13.2-40.3)
05-07 (n=26)	57.7 (36.9-76.6)	84.6 (65.1-95.6)	15.4 (4.4-34.9)	73.1 (52.2-88.4)	26.9 (11.6-47.8)	411 (88-1185)	255 (63-799)	50.0 (29.9-70.1)	34.6 (17.2-55.7)
15-17 (n=49)	69.4 (54.6-81.7)	91.8 (80.4-97.7)	8.2 (2.3-19.6)	77.6 (63.4-88.2)	22.4 (11.8-36.6)	1108 (136-1930)	721 (88-1114)	30.6 (18.3-45.4)	22.4 (11.8-36.6)
3-way p	P=0.009	P=0.85		P=0.83		P=0.40	P=0.58	P=0.87	P=0.76

2-way p	P=0.004	P=0.81	P=0.82	P=0.33	P=0.51	P=0.90	P=0.78
---------	---------	--------	--------	--------	--------	--------	--------

**Sensitivity Analysis: By Expected Length of Treatment****Table S10. Duration of Pivotal Trials Supporting New Drugs and Biologics Across Three Time Periods, Stratified by Expected Length of Treatment**

<b>Characteristics</b>	<b>Duration</b>
	<b>Median (IQR) in weeks</b>
<b>Overall</b>	
95-97 (n=401)	11.0 (4.9-24.0)
05-07 (n=141)	16.0 (6.0-26.0)
15-17 (n=253)	24.0 (12.0-37.6)
3-way p	P<0.001
<b>Expected Length of Treatment</b>	
<b>Acute</b>	
95-97 (n=158)	4.0 (2.9-6.0)
05-07 (n=27)	2.5 (2.0-7.5)
15-17 (n=30)	6.0 (2.0-12.0)
3-way p	P=0.55
<b>Intermediate</b>	
95-97 (n=39)	24.5 (4.0-52.0)
05-07 (n=33)	12.0 (5.2-19.8)
15-17 (n=67)	24.0 (12.0-64.1)
3-way p	P=0.06
<b>Chronic</b>	
95-97 (n=204)	16.0 (8.0-26.0)
05-07 (n=81)	24.0 (12.0-27.3)
15-17 (n=156)	24.0 (12.0-26.1)
3-way p	P=0.005

**Table S11. Duration of Pivotal Trials Included in Indication-Level Approvals for Novel Therapeutics, Stratified by Expected Length of Treatment**

Characteristics	Duration	
	≥1 Trial of ≥6 Months % (95% CI)	≥1 Trial of ≥12 Months % (95% CI)
<b>Overall</b>		
95-97 (n=124)	25.8 (18.4-34.4)	18.5 (12.1-26.5)
05-07 (n=63)	34.9 (23.3-48.0)	19.0 (10.2-30.9)
15-17 (n=106)	46.2 (36.5-56.2)	35.8 (26.8-45.7)
3-way p	P=0.001	P=0.003
<b>Expected Length of Treatment</b>		
<b>Acute</b>		
95-97 (n=53)	1.9 (0.0-10.1)	1.9 (0.0-10.1)
05-07 (n=15)	6.7 (0.2-31.9)	6.7 (0.2-31.9)
15-17 (n=12)	16.7 (2.1-48.4)	16.7 (2.1-48.4)
3-way p	P=0.03	P=0.03
<b>Intermediate</b>		
95-97 (n=10)	70.0 (34.8-93.3)	50.0 (18.7-81.3)
05-07 (n=15)	26.7 (7.8-55.1)	13.3 (1.7-40.5)
15-17 (n=35)	62.9 (44.9-78.5)	45.7 (28.8-63.4)
3-way p	P=0.67	P=0.62
<b>Chronic</b>		
95-97 (n=61)	39.3 (27.1-52.7)	27.9 (17.1-40.8)
05-07 (n=33)	51.5 (33.5-69.2)	27.3 (13.3-45.5)
15-17 (n=59)	42.4 (29.6-55.9)	33.9 (22.1-47.4)
3-way p	P=0.73	P=0.47

**Sensitivity Analyses: Individual Special Regulatory Programs**

**Table S12. Characteristics of Pivotal Trials Supporting Novel Therapeutics Across Three Time Periods, Stratified by Individual Special Regulatory Programs**

	Random-ized	Double-Blinded	Comparator			Endpoint			Patients (Median, IQR)		Duration (Median, IQR)
			Active	Placebo	None	Clinical	Scale	Surrogate	Overall	Intervention	Weeks
<b>Priority Rev.</b>											
Yes											
95-97 (n=88)	84.5 (75.0-91.5)	74.1 (64.1-83.2)	36.9 (26.6-48.1)	44.0 (33.2-55.3)	19.0 (11.3-29.1)	20.2 (12.3-30.4)	6.0 (2.0-13.3)	73.8 (63.1-82.8)	236 (94-421)	148 (63-248)	24.0 (16.0-51.3)
05-07 (n=62)	75.8 (63.3-85.8)	58.1 (44.8-70.5)	37.1 (25.2-50.3)	38.7 (26.6-51.9)	24.2 (14.2-36.7)	37.1 (25.2-50.3)	8.0 (2.7-17.8)	54.8 (41.7-67.5)	344 (107-616)	230 (107-344)	16.0 (7.8-30.3)
15-17 (n=124)	66.1 (57.1-74.4)	53.2 (44.1-62.2)	22.6 (15.6-31.0)	43.5 (34.7-52.7)	33.9 (25.6-42.9)	18.5 (12.1-26.5)	13.7 (8.2-21.0)	67.7 (58.8-75.9)	227 (118-576)	166 (85-357)	24.0 (12.0-50.1)
3-way p	P=0.003	P=0.003	P=0.02	P=1.00	P=0.02	P=0.58	P=0.06	P=0.49	P=0.16	P=0.05	P=0.49
2-way p	P=0.003	P=0.003	P=0.02			P=0.20			P=0.11	P=0.03	P=0.26
No											
95-97 (n=320)	96.1 (93.3-98.0)	80.8 (76.0-85.0)	46.1 (40.5-51.7)	48.3 (42.6-53.9)	5.7 (3.4-8.8)	50.0 (44.4-55.6)	8.5 (5.7-12.2)	41.5 (36.0-47.1)	293 (166-454)	185 (97-290)	8.0 (4.0-16.0)
05-07 (n=79)	87.3 (78.0-93.8)	74.7 (63.6-83.8)	31.6 (21.6-43.1)	55.7 (44.1-66.9)	12.7 (6.2-22.0)	21.5 (13.1-32.2)	13.9 (7.2-23.5)	64.6 (53.0-75.0)	432 (258-647)	252 (162-402)	12.0 (5.0-26.0)
15-17 (n=129)	97.7 (93.3-99.5)	81.4 (73.6-87.7)	35.7 (27.4-44.6)	62.0 (53.1-70.4)	2.3 (0.5-6.6)	27.9 (20.4-36.5)	20.9 (14.3-29.0)	51.1 (42.2-60.1)	549 (441-931)	351 (249-553)	24.0 (12.0-26.1)
3-way p	P=0.94	P=0.94	P=0.02	P=0.007	P=0.40	P<0.001	P<0.001	P=0.02	P<0.001	P<0.001	P<0.001
2-way p	P=0.41	P=0.88	P=0.02			P<0.001			P<0.001	P<0.001	P<0.001
<b>Accelerated</b>											
Yes											
95-97 (n=34)	82.4 (65.5-93.2)	76.5 (58.8-89.3)	38.2 (22.2-56.4)	44.1 (27.2-62.1)	17.6 (6.8-34.5)	11.8 (3.3-27.5)	0	88.2 (72.5-96.7)	196 (88-357)	124 (60-202)	24.0 (16.0-24.0)
05-07 (n=25)	56.0 (34.9-75.6)	28.0 (12.1-49.4)	24.0 (9.4-45.1)	32.0 (14.9-53.5)	44.0 (24.4-65.1)	8.0 (1.0-26.0)	0	92.0 (74.0-99.0)	196 (97-387)	186 (97-256)	20.0 (10.7-24.0)
15-17 (n=23)	34.8 (16.4-57.3)	26.1 (10.2-48.4)	0.0 (0.0-14.8)	34.8 (16.4-57.3)	65.2 (42.7-83.6)	0.0 (0.0-14.8)	0	1.00 (85.2-1.00)	129 (87-198)	124 (64-176)	47.4 (31.5-93.7)
3-way p	P<0.001	P<0.001	P<0.001	P=0.43	P<0.001	P=0.10	NA	P=0.10	P=0.26	P=0.86	P=0.003
2-way p	P<0.001	P<0.001	P<0.001			P=0.24			P=0.18	P=0.73	P<0.001
No											
95-97 (n=374)	94.7 (91.8-96.8)	79.4 (74.8-83.5)	44.7 (39.5-49.9)	47.7 (42.5-52.9)	7.6 (5.1-10.8)	46.7 (41.5-52.0)	8.7 (6.1-12.1)	44.5 (39.4-49.8)	287 (155-447)	175 (97-284)	8.0 (4.3-24.0)
05-07 (n=116)	87.9 (80.6-93.2)	75.9 (67.0-83.3)	36.2 (27.5-45.6)	51.7 (42.3-61.1)	12.1 (6.8-19.4)	32.8 (24.3-42.1)	13.4 (8.1-21.4)	53.4 (44.0-62.8)	463 (243-652)	259 (151-399)	12.0 (5.0-26.0)
15-17 (n=230)	87.0 (81.9-91.0)	71.7 (65.4-77.5)	32.2 (26.2-38.6)	54.8 (48.1-61.3)	13.0 (9.0-18.1)	25.7 (20.1-31.8)	19.1 (14.3-24.8)	55.2 (48.5-61.8)	496 (267-741)	307 (164-473)	24.0 (12.0-26.0)

3-way p	P<0.001	P=0.03	P=0.002	P=0.09	P=0.03	P<0.001	P<0.001	P=0.009	P<0.001	P<0.001	P<0.001
2-way p	P<0.001	P=0.03	P=0.004			P<0.001			P<0.001	P<0.001	P<0.001

**Table S13. Characteristics of Indication-Level Approvals for Novel Therapeutics Across Three Time Periods, Stratified by Individual Special Regulatory Programs**

	≥2 Trials (%, 95% CI)	Comparators (%, 95% CI)		Endpoints (%, 95% CI)		Patients in Aggregated Pivotal Efficacy Trials (Median, IQR)		Duration (%, 95% CI)	
		≥1 Trial Using Any Comparator	Single-Arm Only	≥1 Trial Using Clinical-Type Endpoints	Surrogate Endpoints Only	Overall	Intervention	≥1 Trial of ≥6 Months	≥1 Trial of ≥12 Months
<b>Priority Rev.</b>									
Yes									
95-97 (n=31)	77.4 (58.9-90.4)	87.1 (40.2-96.4)	12.9 (3.6-29.8)	35.5 (19.2-54.6)	64.5 (45.4-80.8)	586 (215-949)	380 (142-569)	48.4 (30.2-66.9)	29.0 (14.2-48.0)
05-07 (n=34)	55.9 (37.9-72.8)	79.4 (62.1-91.3)	20.6 (8.7-37.9)	47.1 (29.8-64.9)	52.9 (35.1-70.2)	601 (163-1055)	396 (161-568)	38.2 (22.2-56.4)	26.5 (12.9-44.4)
15-17 (n=60)	38.3 (26.1-51.8)	71.7 (58.6-82.5)	28.3 (17.5-41.4)	43.3 (30.6-56.8)	56.7 (43.2-69.4)	360 (135-949)	253 (100-669)	48.3 (35.2-61.6)	36.7 (24.6-50.1)
3-way p	P<0.001	P=0.09		P=0.55		P=0.27	P=0.38	P=0.87	P=0.39
2-way p	P<0.001	P=0.10		P=0.48		P=0.24	P=0.38	P=1.00	P=0.47
No									
95-97 (n=93)	81.7 (72.3-89.0)	98.9 (94.2-100)	1.1 (0.0-5.8)	68.8 (58.4-78.0)	31.1 (22.0-41.6)	811 (532-1397)	513 (297-961)	18.3 (11.0-27.6)	15.1 (8.5-24.0)
05-07 (n=29)	65.5 (45.7-82.1)	96.6 (82.2-99.9)	3.4 (0.0-17.8)	51.7 (32.5-70.6)	48.3 (29.4-67.5)	1005 (328-1733)	661 (223-1165)	31.0 (15.3-50.8)	10.3 (2.2-27.4)
15-17 (n=46)	71.7 (56.5-84.0)	97.8 (88.5-99.9)	2.2 (0.0-11.5)	69.6 (54.2-82.3)	30.4 (17.7-45.8)	1646 (1043-2820)	1019 (543-1589)	43.5 (28.9-58.9)	34.8 (21.4-50.2)
3-way p	P=0.13	P=0.57		P=0.86		P<0.001	P=0.001	P=0.002	P=0.01
2-way p	P=0.18	P=0.62		P=0.93		P<0.001	P<0.001	P=0.002	P=0.008
<b>Accelerated</b>									
Yes									
95-97 (n=12)	75.0 (42.8-94.5)	91.7 (61.5-99.8)	8.3 (0.2-38.5)	16.7 (2.1-48.4)	83.3 (51.6-97.9)	756 (399-988)	433 (230-558)	33.3 (9.9-65.1)	16.7 (2.1-48.4)
05-07 (n=13)	69.2 (38.6-90.9)	69.2 (38.6-90.9)	30.8 (9.1-61.4)	7.7 (0.2-36.0)	92.3 (64.0-99.8)	461 (195-658)	261 (195-483)	30.8 (9.1-61.4)	23.1 (5.0-53.8)
15-17 (n=13)	30.8 (9.1-61.4)	30.8 (9.1-61.4)	69.2 (38.6-90.9)	0 (0.0-24.7)	100 (75.3-100)	196 (138-228)	145 (109-221)	76.9 (46.2-95.0)	46.2 (19.2-74.9)
3-way p	P=0.02	P=0.002		P=0.12		P<0.001	P<0.001	P=0.03	P=0.10
2-way p	P=0.03	P=0.003		P=0.15		P<0.001	P=0.002	P=0.03	P=0.13
No									
95-97 (n=112)	81.3 (72.8-88.0)	96.4 (91.1-99.0)	3.6 (1.0-8.9)	65.2 (55.6-73.9)	34.8 (26.1-44.4)	774 (479-1370)	501 (247-851)	25.0 (17.3-34.1)	18.8 (12.0-27.2)
05-07 (n=50)	58.0 (43.2-71.8)	92.0 (80.8-97.8)	8.0 (2.2-19.2)	60.0 (45.2-73.6)	40.0 (26.4-54.8)	831 (252-1564)	435 (145-915)	36.0 (22.9-50.8)	18.0 (8.6-31.4)
15-17 (n=93)	55.9	90.3	9.7	62.4	37.6	1079 (342-2390)	612 (241-1365)	41.9	34.4



	(45.2-66.2)	(82.4-95.5)	(4.5-17.6)	(51.7-72.2)	(27.8-48.3)			(31.8-52.6)	(24.9-45.0)
3-way p	P<0.001	P=0.08		P=0.66		P=0.15	P=0.19	P=0.01	P=0.01
2-way p	P<0.001	P=0.08		P=0.68		P=0.14	P=0.16	P=0.01	P=0.01

**Table S14. Characteristics of Pivotal Trials Supporting Novel Therapeutics Approved by the FDA Across Three Time Periods, Considering Orphan Designation as a Special Regulatory Program**

	Random- ized	Double- Blinded	Comparator			Endpoint			Patients in Pivotal Efficacy Trials (Median, IQR)		Duration (Median, IQR) in Weeks
			Active	Placebo	None	Clinical	Scale	Surrogate	Overall	Interventi on	
<b>Pathway</b>											
Any											
95-97 (n=101)	83.3 (74.4-90.2)	72.0 (61.8-80.9)	36.5 (26.9-46.9)	43.8 (33.6-54.3)	19.8 (12.4-29.2)	24.0 (15.8-33.7)	7.3 (3.0-14.4)	68.8 (58.5-77.8)	236 (94-425)	145 (63-259)	24.0 (15.0-52.3)
05-07 (n=64)	75.0 (62.6-85.0)	56.3 (43.3-68.6)	35.9 (24.3-48.9)	39.1 (27.1-52.1)	25.0 (15.0-37.4)	37.5 (25.7-50.5)	7.8 (2.6-17.3)	54.7 (41.7-67.2)	329 (115-605)	225 (106-336)	17.0 (9.7-28.3)
15-17 (n=133)	68.4 (59.8-76.2)	55.6 (46.8-64.2)	22.6 (15.8-30.6)	45.9 (37.2-54.7)	31.6 (23.8-40.2)	19.5 (13.2-26.3)	14.3 (8.8-21.4)	66.2 (57.5-74.1)	227 (119-655)	167 (84-366)	24.0 (12.0-49.3)
3-way p	P=0.010	P=0.016	P=0.019	P=0.70	P=0.04	P=0.34	P=0.08	P=0.79	P=0.10	P=0.03	P=0.58
2-way p	P=0.011	P=0.012	P=0.03			P=0.23			P=0.08	P=0.02	P=0.33
None											
95-97 (n=305)	97.0 (94.3-98.6)	81.7 (76.8-85.9)	46.6 (40.9-52.3)	48.5 (42.8-54.3)	4.9 (2.8-8.0)	50.0 (44.2-55.8)	8.2 (5.4-11.9)	41.8 (36.2-47.5)	297 (173-450)	186 (100-289)	8.0 (4.0-15.7)
05-07 (n=77)	88.3 (79.0-94.5)	76.6 (65.6-85.5)	32.5 (22.2-44.1)	55.8 (44.1-67.2)	11.7 (5.5-21.0)	20.8 (12.4-31.5)	14.3 (7.4-24.1)	64.9 (53.2-75.5)	455 (273-651)	254 (163-409)	12.0 (5.0-26.0)
15-17 (n=120)	97.5 (92.9-99.5)	80.8 (72.6-87.4)	36.7 (28.1-45.9)	60.8 (51.5-69.6)	2.5 (0.5-7.1)	27.5 (19.7-36.4)	20.8 (14.0-29.2)	51.7 (42.4-60.9)	548 (446-958)	344 (254-580)	24.0 (12.0-26.0)
3-way p	P=0.69	P=0.71	P=0.03	P=0.018	P=0.63	P<0.001	P<0.001	P=0.016	P<0.001	P<0.001	P<0.001
2-way p	P=0.77	P=0.84	P=0.06			P<0.001			P<0.001	P<0.001	P<0.001

**Table S15. Characteristics of Indication-Level Approvals for Novel Therapeutics Approved by the FDA Across Three Time Periods, Considering Orphan Designation as a Special Regulatory Program**

	≥2 Trials (%, 95% CI)	Comparators (%, 95% CI)		Endpoints (%, 95% CI)		Patients in Aggregated Pivotal Efficacy Trials (Median, IQR)		Duration (%, 95% CI)	
		≥1 Trial Using Any Comparator	Single-Arm Only	≥1 Trial Using Clinical Endpoints or Clinical Scales	Trials Using Surrogate Endpoints Only	Overall	Intervention	≥1 Trial of ≥6 Months	≥1 Trial of ≥12 Months
<b>Pathway</b>									
Any									
95-97 (n=35)	77.1 (59.9-89.6)	88.6 (73.3-96.8)	11.4 (3.2-26.7)	40.0 (23.9-57.9)	60.0 (42.1-76.1)	586 (244-949)	380 (151-569)	48.6 (31.4-66.0)	31.4 (16.9-49.3)
05-07 (n=36)	52.8 (35.5-69.6)	77.8 (60.8-89.9)	22.2 (10.1-39.2)	47.2 (30.4-64.5)	52.8 (35.5-69.6)	534 (166-979)	340 (119-544)	36.1 (20.8-53.8)	25.0 (12.1-42.2)
15-17 (n=68)	35.3 (24.1-47.8)	75.0 (63.0-84.7)	25.0 (15.3-37.0)	45.6 (33.5-58.1)	54.4 (41.9-66.5)	360 (129-1071)	253 (89-574)	48.6 (36.2-61.0)	35.3 (24.1-47.8)
3-way p	P<0.001	P=0.12		P=0.64		P=0.22	P=0.32	P=0.83	P=0.57
2-way p	P<0.001	P=0.11		P=0.59		P=0.16	P=0.27	P=1.00	P=0.70
None									
95-97 (n=89)	82.0 (72.5-89.4)	98.9 (93.9-100)	1.1 (0.0-6.1)	68.5 (57.8-78.0)	31.5 (22.0-42.2)	811 (535-1397)	514 (308-961)	16.9 (9.8-26.3)	13.5 (7.2-22.4)
05-07 (n=27)	70.4 (49.8-86.2)	100 (87.2-100)	0.0 (0.0-12.8)	51.9 (31.9-71.3)	48.1 (28.7-68.1)	1167 (419-1835)	680 (244-1374)	33.3 (16.5-54.0)	11.1 (2.4-29.2)
15-17 (n=38)	84.2 (68.7-94.0)	97.4 (86.2-99.9)	2.6 (0.0-13.8)	71.1 (54.1-84.6)	28.9 (15.4-45.9)	1833 (1207-3180)	1089 (715-1887)	42.1 (26.3-59.2)	36.8 (21.8-54.0)
3-way p	P=0.99	P=0.58		P=0.96		P<0.001	P<0.001	P=0.002	P=0.005
2-way p	P=0.77	P=0.54		P=0.78		P<0.001	P<0.001	P=0.003	P=0.003